Table 3.

Relative Risk for Continuous Clinical Outcomes of all Study Infants

	SGA			AGA
Continuous outcomes	Vitamin A (n = 50)	Control (n = 54)	p value for treatment difference within SGA	Vitamin A (n = 355)	Control (n = 348)	p value for treatment difference within AGA	p value for GA group and treatment interaction	p-value for difference between SGA and AGA groups
Fraction of inspired oxygen, median (5th, 95th percentiles)
36 wk	0.21 (0.21, 1.0)	0.26 (0.21, 1.0)	0.50	0.23 (0.21, 1.0)	0.25 (0.21, 1.0)	0.98		0.48
28 d	0.30 (0.21, 0.58)	0.32 (0.21, 0.75)	0.14	0.34 (0.21, 0.87)	0.32 (0.21, 0.80)	0.74		0.64
Length of hospitalization, median (5th, 95th percentiles)
Infants who survived	91 (54, 176)	90 (55, 242)	0.85	95 (62, 168)	94 (57, 166)	0.40	0.07	0.13
Infants who died	20 (6, 213)	20 (5, 141)	0.56	20 (3, 226)	19 (5, 152)	0.37	0.09	0.51

Abbreviations: AGA, average for gestational age; GA, gestational age; SGA, small for gestational age.

Note: For FIO₂, p values were obtained using Wilcoxon rank sum tests adjusting for gestational age. For length of hospitalization, a Poisson model assuming an interaction between treatment and GA group was used to obtain p values. The model controlled for GA.